Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.
- Cancer Biomarker Study Data Presented at the 2011 AACR Meeting
A roundup of five research studies on cancer biomarkers that were presented earlier this week at the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Florida.
- 2010 Australian Biomarker Discovery Conference Summary: Biomarkers in the Next Decade
In the February edition of the journal Pharmacogenomics (Future Medicine), Greg Gibson from the School of Biology at the Georgia Institute of Technology provides a summary of talks and discussion from the Inaugural Australian Biomarker Discovery Conference (BDC 2010) held in Shoal Bay, Australia in December.
- Clusterin Not a Potential Early Biomarker for Alzheimer’s Disease Development
According to a recent study published in the Journal of the American Medical Association, plasma clusterin levels are significantly associated with prevalence and severity of Alzheimer’s disease (AD), but not with incidence.
- Sage Bionetworks Partners with CHDI Foundation, Takeda for Neurobiology
Sage Bionetworks has started projects to build advanced computational models of neurobiological disease through two ongoing partnerships with the CHDI Foundation and Takeda Pharmaceuticals.
- Case Western Bioinformatics Spinoff NeoProteomics Signs Licensing Deal
Late last month, NeoProteomics, a bioinformatics spinoff company from Case Western Reserve University, signed an exclusive option agreement to license technology from the university.